Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 3:1-10.
doi: 10.1159/000546080. Online ahead of print.

St. Gallen/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference

Nina Ditsch  1   2 , Michael Gnant  3   4 , Christoph Thomssen  5 , Nadia Harbeck  6
Affiliations
Review

St. Gallen/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference

Nina Ditsch et al. Breast Care (Basel). .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Breast Care (Basel). 2025 Aug 19. doi: 10.1159/000547496. Online ahead of print. Breast Care (Basel). 2025. PMID: 41063772 Free PMC article.

Abstract

Background: In 2025, the St. Gallen Conference was held from March 12th-15th, with the largest attendance since the pandemic and more than 3,000 participants from over 100 countries.

Summary: The conference chairs professionally guided through the program on Early Breast Cancer, featuring abstracts submitted from all over the world. In addition, Prof. Dr. Herold J. Burstein (USA) led the panel through the difficult topics of local and systemic treatment modalities in an excellent, clearly structured and engaging way. Almost 80 experts from all continents and more than 30 nations formed the panel and summarized the current literature in excellent presentations and discussions.

Key messages: Final voting covered the topics of genetic testing, DCIS, breast and axillary surgery, radiation therapy, systemic treatment based on subtypes, treatment of the elderly, therapy of local-regional recurrence and oligometastatic breast cancer.

Keywords: Adjuvant treatment; Consensus; Early-stage breast cancer; Radiation; St. Gallen Conference; Surgery; Systemic treatment.

PubMed Disclaimer

Conflict of interest statement

Nina Ditsch is on the advisory boards of Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Seagen, and Exact Sciences; participated in lectures and speakers bureaus at AstraZeneca, Daiichi-Sankyo, Exact Sciences, Pierre-Fabre, I-Med-Institute, Merit-Medical, pfm medical, Medi-Seminar GmbH, Roche, Lilly, Pfizer, Gilead, Novartis, Onkowissen, Jörg Eickeler Kongress, and if-Kongress; received manuscript support from pfm medical ag; and received trial funding from Gilead and BZKF. Michael Gnant received personal fees/travel support from Amgen, AstraZeneca, Bayer, Daiichi-Sankyo, EliLilly, EPG Health (IQVIA), Menarini-Stemline, MSD, Novartis, Pierre-Fabre, and Veracyte. Christoph Thomssen received honoraria as compensation for lectures and medical expertise from Rottalinn-Kliniken, Klinikum Basel, Onkowissen TV, ESMO, and BfArM (Federal Institute for Drugs and Medical Devices). Nadia Harbeck received honoraria for lectures and/or consulting from AstraZeneca, Daiichi-Sankyo, Gilead, Lilly, MSD, Novartis, Pierre-Fabre, Pfizer, Roche, Sandoz, Seagen, and Viatris and is co-director of West German Study Group (WSG). Nina Ditsch, Michael Gnant, Christoph Thomssen, and Nadia Harbeck were members of the journal’s Editorial Board at the time of submission.

Figures

Fig. 1.
Fig. 1.
Voting of the auditorium (a) and the panel (b): follow-up after diagnosis of early-stage breast cancer by a cancer specialist should last at least 5 years.
See this image and copyright information in PMC

References

    1. Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, Ausems MG, Collée JM, Jansen L, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136(3):668–77. - PubMed
    1. Heemskerk-Gerritsen BAM, Jager A, Koppert LB, Obdeijn AI, Collée M, Meijers-Heijboer HEJ, et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019;177(3):723–33. - PMC - PubMed
    1. Galimberti V, Vicini E, Corso G, Morigi C, Fontana S, Sacchini V, et al. Nipple-sparing and skin-sparing mastectomy: review of aims, oncological safety and contraindications. Breast. 2017;34(Suppl 1):S82–4. - PMC - PubMed
    1. Meattini I, Becherini C, Boersma L, Kaidar-Person O, Marta GN, Montero A, et al. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol. 2022;23(1):e21–31. - PubMed
    1. Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613–26. - PMC - PubMed

LinkOut - more resources